Pyridine indole hybrids as novel potent CYP17A1 inhibitors
Journal of Enzyme Inhibition and Medicinal Chemistry · 2025
DOI: 10.1080/14756366.2025.2463014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2025. Verfasst von Tomasz M Wróbel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Medical University of Lublin, Lublin, Poland. Hauptthemen laut MEDLINE: Steroid 17-alpha-Hydroxylase, Pyridines, Indoles, Enzyme Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Cancer Research Switzerland, Swiss Government Excellence Scholarship.
Abstract (Originalsprache)
Prostate cancer (PCa) is one of the most prevalent malignancies affecting men worldwide, and androgen deprivation therapy (ADT) is a primary treatment approach. CYP17A1 inhibitors like abiraterone target the steroidogenic pathway to reduce androgen levels, but their clinical efficacy is limited by drug resistance and adverse effects. This study reports the synthesis and evaluation of novel CYP17A1 inhibitors derived from a previously identified hit compound. Several analogs were synthesised, including an unexpected di-cyano derivative, which demonstrated increased potency against CYP17A1 compared to abiraterone. Biological assays revealed that these compounds significantly inhibited CYP17A1 enzymatic activity and altered steroid biosynthesis. Among the newly synthesised inhibitors, compound 11 showed the highest potency (IC50 = 4 nM) and the related compound 14 presented a template for further development. A combined docking and molecular dynamics approach was used to identify the possible target binding modes of the compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Medical University of Lublin, Lublin, Poland.
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
- Pediatric Endocrinology, Department of Pediatrics, University Children's Hospital, University of Bern, Bern, Switzerland.
- Translational Hormone Research Program, Department of Biomedical Research, University of Bern, Bern, Switzerland.
- Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
- Department of Nephrology and Hypertension, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland.
Förderung
- National Science Centre
- Cancer Research Switzerland
- Swiss Government Excellence Scholarship
Zitieren
APA
Wróbel, T. M., Grudzińska, A., Yakubu, J., du Toit, T., Sharma, K., Harrington, J. C., Björkling, F., Jørgensen, F. S., & Pandey, A. V. (2025). Pyridine indole hybrids as novel potent CYP17A1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2025.2463014
Vancouver
Wróbel TM, Grudzińska A, Yakubu J, du Toit T, Sharma K, Harrington JC, et al. Pyridine indole hybrids as novel potent CYP17A1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 2025. doi:10.1080/14756366.2025.2463014
BibTeX
@article{Wrbel2025,
author = {Wróbel, Tomasz M and Grudzińska, Angelika and Yakubu, Jibira and du Toit, Therina and Sharma, Katyayani and Harrington, Jeremiah C and Björkling, Fredrik and Jørgensen, Flemming Steen and Pandey, Amit V},
title = {Pyridine indole hybrids as novel potent CYP17A1 inhibitors},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2025},
doi = {10.1080/14756366.2025.2463014}
}
EUVIMED